These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25478082)

  • 21. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature.
    Lacro JP; Dunn LB; Dolder CR; Leckband SG; Jeste DV
    J Clin Psychiatry; 2002 Oct; 63(10):892-909. PubMed ID: 12416599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Attitudes toward Medication and Reasons for Non-Compliance in Patients with Schizophrenia.
    Chandra IS; Kumar KL; Reddy MP; Reddy CM
    Indian J Psychol Med; 2014 Jul; 36(3):294-8. PubMed ID: 25035554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Compliance in psychoses.
    Kampman O; Lehtinen K
    Acta Psychiatr Scand; 1999 Sep; 100(3):167-75. PubMed ID: 10493082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of noncompliance in patients with schizophrenia.
    Perkins DO
    J Clin Psychiatry; 2002 Dec; 63(12):1121-8. PubMed ID: 12523871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A study of reasons of non-compliance of psychiatric treatment and patients' attitudes towards illness and treatment in Qatar.
    Bener A; Dafeeah EE; Salem MO
    Issues Ment Health Nurs; 2013 Apr; 34(4):273-80. PubMed ID: 23566190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The meaning of antipsychotic medication to patients with schizophrenia.
    Seeman MV; Seeman N
    J Psychiatr Pract; 2012 Sep; 18(5):338-48. PubMed ID: 22995961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder.
    Moncrieff J; Gupta S; Horowitz MA
    Ther Adv Psychopharmacol; 2020; 10():2045125320937910. PubMed ID: 32670542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The meaning and management of neuroleptic medication: a study of patients with a diagnosis of schizophrenia.
    Rogers A; Day JC; Williams B; Randall F; Wood P; Healy D; Bentall RP
    Soc Sci Med; 1998 Nov; 47(9):1313-23. PubMed ID: 9783874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subjective illness theory and antipsychotic medication compliance by patients with schizophrenia.
    Holzinger A; Loffler W; Muller P; Priebe S; Angermeyer MC
    J Nerv Ment Dis; 2002 Sep; 190(9):597-603. PubMed ID: 12357093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psychosis patients' knowledge, adherence and attitudes towards the naming of antipsychotic medication in Hong Kong.
    Lau KC; Lee EH; Hui CL; Chang WC; Chan SK; Chen EY
    Early Interv Psychiatry; 2015 Oct; 9(5):422-7. PubMed ID: 25244594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A cross-sectional observational study of healthcare professional views of factors affecting teenage adherence with antipsychotic medication.
    Ramdour S; Duxbury JA; Becket G; Wilson S
    J Psychiatr Ment Health Nurs; 2015 Sep; 22(7):491-501. PubMed ID: 25990303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Depot haloperidol decanoate for schizophrenia.
    Quraishi S; David A
    Cochrane Database Syst Rev; 2000; 1999(2):CD001361. PubMed ID: 10796438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Depot-medication compliance for patients with psychotic disorders: the importance of illness insight and treatment motivation.
    Noordraven EL; Wierdsma AI; Blanken P; Bloemendaal AF; Mulder CL
    Neuropsychiatr Dis Treat; 2016; 12():269-74. PubMed ID: 26893565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of schizophrenic patients with depot-neuroleptics.].
    Sigursteinsson G; Thorleifsson K
    Laeknabladid; 1997 Jan; 83(1):20-9. PubMed ID: 19679930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subjective side effects of antipsychotics and medication adherence in people with schizophrenia.
    McCann TV; Clark E; Lu S
    J Adv Nurs; 2009 Mar; 65(3):534-43. PubMed ID: 19222651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influences on therapist's decisions for neuroleptic treatment in schizophrenia: the role of characteristics of the patient and the physician.
    Franz M; Ranger J; Hanewald B; Gallhofer B; Lay B
    Pharmacopsychiatry; 2012 Nov; 45(7):261-8. PubMed ID: 22648306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated DISC1 transcript levels in PBMCs during acute psychosis in patients with schizophrenia.
    Olincy A; House R; Gao B; Recksiek P; Phang TL; Sullivan B; Hollis JP; Hopkins J; Shade T; Edwards MG; Vianzon R; Griffiths C; Ceilley J; Helfrich RW; Ritvo J; Weis E; Weiss D; Gault J
    Transl Biomed; 2011; 2(1):. PubMed ID: 22319686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insight across mental disorders: A multifaceted metacognitive phenomenon.
    Konstantakopoulos G
    Psychiatriki; 2019; 30(1):13-16. PubMed ID: 31115349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis.
    Donohoe G; Owens N; O'Donnell C; Burke T; Moore L; Tobin A; O'Callaghan E
    Eur Psychiatry; 2001 Aug; 16(5):293-8. PubMed ID: 11514132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subjective response to neuroleptics in schizophrenia.
    Awad AG
    Schizophr Bull; 1993; 19(3):609-18. PubMed ID: 7901897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.